



上海源叶生物科技有限公司  
 Shanghai yuanye Bio-Technology Co., Ltd  
 电话: 021-61312973 传真: 021-55068248  
 网址: www.shyuanye.com  
 邮箱: shyysw@sina.com


产品名称: (R)-N-(2,3-二氢-1H-茚基)腺苷  
 产品别名: PD 117519; CI947

生物活性:																											
<b>Description</b>	PD 117519 (CI947) is an A <sub>2A</sub> adenosine agonist which has shown oral antihypertensive activity in pharmacological animal models[1][2].																										
<b>IC<sub>50</sub> &amp; Target</b>	A <sub>2A</sub> adenosine[1]																										
<b>In Vivo</b>	PD 117519 (2-10 mg/kg; oral administration; 16-24 hours; male beagle dogs) treatment produces significant hemodynamic changes at T <sub>max</sub> (4 hours) follows by acute coronary vascular injury that is evident at 16 hours postdosing. Treatment with 2 or 10 mg/kg of PD 117519 produces significant increases in mean heart rate and decreases in mean indirect systolic blood pressure at time of highest drug exposure, 4 hours postdosing[3].																										
	<b>Animal Model:</b> 24 male beagle dogs (8-12 months old)[3]																										
	<b>Dosage:</b> 2 mg/kg or 10 mg/kg																										
	<b>Administration:</b> Oral administration; 16 hours and 24 hours																										
	<b>Result:</b> Increased in mean heart rate and decreased in mean indirect systolic blood pressure at time of highest drug exposure. Induced acute coronary arteriopathy. The endothelium also appears injured.																										
<b>Solvent&amp;Solubility</b>	<b>In Vitro:</b> DMSO : ≥ 100 mg/mL (260.82 mM) * "≥" means soluble, but saturation unknown.																										
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th>Solvent</th> <th>Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th>Concentration</th> <th></th> </tr> </thead> <tbody> <tr> <td></td> <td>1 mM</td> <td></td> <td>2.6082 mL</td> <td>13.0412 mL</td> <td>26.0824 mL</td> </tr> <tr> <td></td> <td>5 mM</td> <td></td> <td>0.5216 mL</td> <td>2.6082 mL</td> <td>5.2165 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td></td> <td>0.2608 mL</td> <td>1.3041 mL</td> <td>2.6082 mL</td> </tr> </tbody> </table>	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg	Concentration			1 mM		2.6082 mL	13.0412 mL	26.0824 mL		5 mM		0.5216 mL	2.6082 mL	5.2165 mL		10 mM		0.2608 mL	1.3041 mL	2.6082 mL
	Preparing Stock Solutions		Solvent	Mass				1 mg	5 mg	10 mg																	
		Concentration																									
		1 mM		2.6082 mL	13.0412 mL	26.0824 mL																					
		5 mM		0.5216 mL	2.6082 mL	5.2165 mL																					
		10 mM		0.2608 mL	1.3041 mL	2.6082 mL																					
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。																										
	<b>In Vivo:</b> 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶																										
	1.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline)																										
Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution																											
此方案可获得 ≥ 2.5 mg/mL (6.52 mM, 饱和度未知) 的澄清溶液。																											
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理																											



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

	<p>盐水水溶液中，混合均匀。</p> <p>2.请依序添加每种溶剂： 10% DMSO →90% corn oil</p> <p>Solubility: <math>\geq 2.5</math> mg/mL (6.52 mM); Clear solution</p> <p>此方案可获得 <math>\geq 2.5</math> mg/mL (6.52 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 <math>\mu</math>L 25.0 mg/mL 的澄清 DMSO 储备液加到 900 <math>\mu</math>L 玉米油中，混合均匀。</p>
<b>References</b>	<p>[1]. Reynolds DL, et al. Liquid chromatographic analysis of the adenosine agonist PD 117519 in dog plasma. J Pharm Biomed Anal. 1991;9(4):345-9.</p> <p>[2]. Tobin GA, et al. The role of eNOS phosphorylation in causing drug-induced vascular injury. Toxicol Pathol. 2014 Jun;42(4):709-24.</p> <p>[3]. Enerson BE, et al. Acute drug-induced vascular injury in beagle dogs: pathology and correlating genomic expression. Toxicol Pathol. 2006;34(1):27-32.</p>



源叶生物